Tiraglolumab plus atezolizumab with chemoradiation for anal cancer
Part of Cancer clinical trials.
This Phase 2 trial tests whether adding tiraglolumab and atezolizumab to standard chemoradiation can improve outcomes for people with localized anal canal squamous cell cancer that has not spread to distant organs. It may help the immune system work better alongside treatment to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign the consent form.
- Your cancer is squamous cell carcinoma of the anal canal (a specific cancer type).
- Your cancer has not spread to distant organs (stage I, II, IIIA, or IIIB).
- You can have chemoradiation for cure and have at least one measurable area doctors can track.
- You have a recent or stored biopsy sample available for research testing.
- Your general strength is good (ECOG 0–1), and blood tests show your body can handle treatment (counts, liver/kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.
Hear when a new Squamous Cell Carcinoma of the Anal Canal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.